{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"pt-141-muscle-loss","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-muscle-loss/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/pt-141-muscle-loss/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-muscle-loss/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-muscle-loss/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-muscle-loss/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/pt-141-muscle-loss/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/pt-141-muscle-loss/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"pt-141-muscle-loss","title":"PT-141 for Muscle Loss: Evidence Review","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:41:07.807Z","body_excerpt":"## What's breaking down\n\nMuscle loss, or sarcopenia in clinical terms, involves progressive decline in muscle mass, strength, and function. This happens when protein breakdown outpaces repair in muscle tissue. Layers include reduced anabolic signaling, inflammation, hormonal shifts, inactivity, and neural drive changes. Over time, fewer motor units fire effectively and satellite cells repair less efficiently. The result is frailty and reduced physical capacity. No direct peptide catalog entry replaces addressing these layers through established means.\n\n## Why PT-141 might help you\n\nPT-141 acts primarily on melanocortin receptors in the central nervous system to influence arousal pathways. The peptide chain focuses on the sexual / CNS arousal layer.\n\n1. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nIf reduced sexual activity or CNS drive contributes to lower overall movement and muscle maintenance, some discuss PT-141 in that context. This remains indirect. No data show direct effects on muscle protein synthesis or satellite cell activity. Any potential link would sit at the speculative tier for muscle loss specifically.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **PT-141** → sexual / CNS arousal\n\nThis section maps layers without repetition. PT-141 addresses one narrow pathway. Other compounds would address separate degeneration layers if present.\n\n## What the evidence actually shows\n\nHuman trials of PT-141 (bremelanotide) center on hypoactive sexual desire disorder and erectile dysfunction. Phase 3 RECONNECT trials (two identical randomized, double-blind, placebo-controlled studies) enrolled premenopausal women and showed statistically significant gains in desire scores and reductions in distress versus placebo (human tier). No endpoints measured muscle mass, strength, or sarcopenia markers (human tier for sexual outcomes; absent for muscle).\n\nPreclinical data are limited to melanocortin effects in animal models of sexual function, with no published rat or mouse studies on muscle wasting or hypertrophy (preclinical tier: none identified for muscle loss).\n\nAnecdotal reports on forums mention libido changes but contain no consistent descriptions of muscle gain or reversal of muscle loss (anecdotal tier).\n\nMarketing or clinic sites sometimes list PT-141 alongside muscle-related peptides, yet explicit statements confirm absence of supporting clinical research for muscle mass increases (mechanistic tier: melanocortin agonism does not target muscle regulatory pathways).\n\n## What scientists say\n\nPublished reviews and trial reports emphasize PT-141's role in central melanocortin activation for desire, without reference to anabolic or anti-catabolic muscle effects. Researchers note side effects such as nausea and transient blood pressure changes in human studies. No expert statements link the compound to muscle regeneration pathways (human tier for approved indications; speculative for muscle).\n\n## What people say on Reddit\n\nReddit threads discuss PT-141 experiences primarily for libido and erectile function. Users report subjective increases in desire or performance but rarely mention muscle-related outcomes. Isolated posts note general energy feelings alongside workouts, yet these remain personal anecdotes without controlled measurement (anecdotal tier).\n\n## What people say on X\n\nX posts echo similar themes: emphasis on arousal effects rather than body composition changes. No prominent verified accounts or threads detail measurable muscle preservation or gains attributable to PT-141 (anecdotal tier).\n\n## What we do not know\n\nNo human trials examine PT-141 in populations with documented muscle loss. Long-term effects on muscle protein balance, mitochondrial function in muscle, or interaction with resistance tra","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"No scientific evidence or clinical research proves PT-141 increases muscle mass.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Direct statement from review of PT-141 and muscle growth.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c2","text":"RECONNECT phase 3 trials showed statistically significant improvements in sexual desire and reduced distress versus placebo in women with HSDD.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Core efficacy data from randomized controlled trials.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c3","text":"PT-141 does not target muscle tissue regulatory processes for hypertrophy.","tier":"mechanistic","weight":0.3,"section":"Why PT-141 might help you","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Explains absence of muscle-specific mechanism.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false}],"sources":[{"id":"s1","type":"other","url":"https://conciergemdla.com/blog/pt-141-for-mucsle-growth/","title":"Is PT-141 Used To Build Muscle Mass?","quote":"Currently, there is no scientific evidence or clinical research that proves the use of PT-141 will increase muscle mass.","summary":"Explicit statement of no evidence for muscle mass effects.","claim_ids":["c1","c3"],"link_status":"ok","quote_status":"verified","hash":"cf5727831ea273bdaf9a76917098bf6c4d490a30255437f1a53f96b4f1172593"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.","summary":"Summary of phase 3 RECONNECT trial results.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"11243c86b47e4c8f32e2907cbcaf0bfd7837cbf068f889d6a312f37cc759f695"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31599840/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.","summary":"Summary of phase 3 RECONNECT trial results.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"11243c86b47e4c8f32e2907cbcaf0bfd7837cbf068f889d6a312f37cc759f695"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"pt-141-muscle-loss","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":3,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":3,"claims_total":3,"sources":2,"anecdotal":0,"scientific":1,"user_reports":0,"questions":0,"evidence_ingests":0}}